Log in

Relevant bibliographies by topics / Fatty liver disease / Journal articles

To see the other types of publications on this topic, follow the link: Fatty liver disease.

Journal articles on the topic 'Fatty liver disease'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Fatty liver disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Fujioka, Kazumi. "Link between Non-Alcoholic Fatty Liver Disease and Hypertension: Non-Alcoholic Fatty Liver Disease as a Multisystem Disease." International Journal of Clinical Case Reports and Reviews 10, no. 5 (2022): 01–04. http://dx.doi.org/10.31579/2690-4861/203.

Full text

Abstract:

The prevalence and incidence of non-alcoholic fatty liver disease (NAFLD) is increasing due to the epidemics of obesity and type 2 diabetes mellitus (T2DM). Many studies provided the evidence of the decreased flow-mediated vasodilation (FMD), increased carotid intima-media thickness (IMT), and increased brachial ankle pulse wave velocity (baPWV) in patients with NAFLD. Recently, a link between NAFLD and hypertension along with new genetic expression, ADIPOQ C11377G and AGTR1 has been shown. It is putative that NAFLD may induce systemic inflammation, insulin resistance, oxidative stress, and in

APA, Harvard, Vancouver, ISO, and other styles

2

L Pathan, Fayaj. "Nonalcoholic Fatty Liver Disease (NAFLD) A Chronic Liver Disease." Acta Scientifci Nutritional Health 4, no. 1 (2019): 58. http://dx.doi.org/10.31080/asnh.2020.04.nonalcoholic-fatty-liver-disease-nafld-a-chronic-liver-disease.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mirzakarimova, Farida, Svetlana Kaleda, Natalia Polikarpova, and Abdumurad Babadjanov. "NONALCOHOLIC FATTY LIVER DISEASE -SOME ASPECTS OF PREVENTION." UZBEK MEDICAL JOURNAL 2, no. 2 (2021): 15–24. http://dx.doi.org/10.26739/2181-0664-2021-2-3.

Full text

Abstract:

Nowadays, NAFLD is considered one of the leading causes of chronic liver diseases globally.This is probably becausea patient with NAFLD usually had more severe diseases -diabetes mellitus type 2 (DM-2), metabolic syndrome, etc. On the one hand, after it was established that insulin resistance underlies these metabolic diseases and, on the other hand, that compensationfor these conditions does not eliminate NAFLD, and the presence of NAFLD worsens the course of the underlying disease, interest in its study increased significantly. The development of NAFLD is increasingly associated with the hyp

APA, Harvard, Vancouver, ISO, and other styles

4

kadhium, Athraa fouad. "Fighting Fatty Liver Disease: Pathogenesis and Therapeutic Approaches." International Journal of Medical Science and Dental Health 10, no. 08 (2024): 27–38. http://dx.doi.org/10.55640/ijmsdh-10-08-03.

Full text

Abstract:

FLD is a burgeoning international ailment closely associated with the increasing rates of obesity, type II diabetes mellitus and physical inactivity. This review focuses on the various aspects of FLD pathophysiology including genetic susceptibility, metabolic disturbances, inflammation, oxidative stress, and environmental factors. Diagnostic tests can be simple and non-invasive such as imaging and biomarkers and can be relatively invasive, such as liver biopsies. Currently the treatment focus is made on drug and surgical interventions with lifestyle changes, and besides, gene and stem cell the

APA, Harvard, Vancouver, ISO, and other styles

5

Babaalizadeh, Behina, Maryam Bahmanyar, Mohammad Hassan Meshkibaf, and Behnoosh Miladpour. "Fatty Liver, Developing Factors and the Outcomes." International Journal of Forensic Research 5, no. 1 (2024): 192–202. http://dx.doi.org/10.33140/ijfr.05.01.01.

Full text

Abstract:

Fatty liver has grown increasingly in recent decades. Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in the United States with a prevalence of 30% and the leading cause of liver disease with a mortality rate of 25.2% in the world. Fatty liver is divided into two types, alcoholic and non-alcoholic. It has been reported that 44% of NAFLD patients progress to nonalcoholic steatohepatitis (NASH) at the second biopsy, and in several countries, hepatocellular carcinoma is the most common disease. Unfortunately, no absolute cure has yet been found. Finding out

APA, Harvard, Vancouver, ISO, and other styles

6

Brody, Herb. "Fatty liver disease." Nature 551, no. 7681 (2017): S85. http://dx.doi.org/10.1038/d41586-017-06927-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Sanyal, Arun. "Fatty Liver Disease." Seminars in Liver Disease 28, no. 04 (2008): 337. http://dx.doi.org/10.1055/s-0028-1091977.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Softic, Samir, and C. Ronald Kahn. "Fatty liver disease." European Journal of Gastroenterology & Hepatology 31, no. 1 (2019): 143. http://dx.doi.org/10.1097/meg.0000000000001279.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Petts, Gemma, Kirsty Lloyd, and Robert Goldin. "Fatty liver disease." Diagnostic Histopathology 20, no. 3 (2014): 102–8. http://dx.doi.org/10.1016/j.mpdhp.2014.01.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hampton, Tracy. "Fatty Liver Disease." JAMA 305, no. 21 (2011): 2162. http://dx.doi.org/10.1001/jama.2011.724.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Polyzos, Stergios. "Fatty liver disease." Maturitas 173 (July 2023): 58. http://dx.doi.org/10.1016/j.maturitas.2023.04.124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Kravchenko, S., N. Kozlova, O. Tirikova та V. Bakhtairova. "АНТИОКСИДАНТЫ КАК ПОТЕНЦИАЛЬНЫЕ БИОМАРКЕРЫ СТАДИЙ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ". Baikal Medical Journal 2, № 4 (2023): 24–32. http://dx.doi.org/10.57256/2949-0715-2023-4-24-32.

Full text

Abstract:

Nonalcoholic fatty liver disease is a complex and multifactorial pathology associated with multiple epigenetic, genetic and environmental factors, and its pathogenesis is still not fully understood. Nonalcoholic fatty liver disease begins with simple steatosis and progresses to nonalcoholic steatohepatitis, which is characterized by signs of oxidative stress, increased lipid peroxidation activity, inflammation, fibrosis, and apoptosis. Antioxidant deficiency is important in the pathogenesis of nonalcoholic fatty liver disease, as it is they that cause the transition of steatosis to steatohepat

APA, Harvard, Vancouver, ISO, and other styles

13

Ruzikulova, Munira Shukhrat kizi, and Malika Khudaiberganovna Ibragimova. "A Literature Review on Fatty Liver Disease." medtigo Journal of Medicine 2, no. 4 (2024): e14324454. https://doi.org/10.5281/zenodo.14324454.

Full text

Abstract:

In the structure of chronic liver diseases, the most common are non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), viral hepatitis B and C. Alcoholic disease has no geographical boundaries. All over the world people continue to drink alcohol, causing irreparable harm to their health. It is believed that drinking more than 80 g of ethanol per day (1 liter of wine, about 3.6 liters of beer and approximately 250 g of strong alcoholic beverages) can lead to clinically obvious liver disease in men. In women, this dose is 2-4 times less. However, the risk of developing al

APA, Harvard, Vancouver, ISO, and other styles

14

Bisaccia, Giandomenico, Fabrizio Ricci, Cesare Mantini, et al. "Nonalcoholic fatty liver disease and cardiovascular disease phenotypes." SAGE Open Medicine 8 (January 2020): 205031212093380. http://dx.doi.org/10.1177/2050312120933804.

Full text

Abstract:

Nonalcoholic fatty liver disease is increasingly recognized as a major global health problem. Intertwined with diabetes, metabolic syndrome, and obesity, nonalcoholic fatty liver disease embraces a spectrum of liver conditions spanning from steatosis to inflammation, fibrosis, and liver failure. Compared with the general population, the prevalence of cardiovascular disease is higher among nonalcoholic fatty liver disease patients, in whom comprehensive cardiovascular risk assessment is highly desirable. Preclinical effects of nonalcoholic fatty liver disease on the heart include both metabolic

APA, Harvard, Vancouver, ISO, and other styles

15

Hiroshi, Bando. "Trend for Clinical Use of Metabolic Associated Fatty Liver Disease (MAFLD)." Asploro Journal of Biomedical and Clinical Case Reports 4, no. 2 (2021): 99–102. https://doi.org/10.36502/2021/ASJBCCR.6237.

Full text

Abstract:

The problems among obesity, diabetes mellitus (DM), fatty liver, metabolic dysfunction have been prevalent, and diagnostic criteria as non-alcoholic fatty liver disease (NAFLD) has been used in practice. When diagnosing NAFLD, to exclude other related liver diseases was necessary, including excessive alcohol intake. The international experts proposed the proper term from NAFLD to metabolic associated fatty liver disease (MAFLD). MAFLD criteria include the evidence of the presence of hepatic steatosis associated with three situations. They are obesity/overweight, presence of Type 2 DM (T2DM), o

APA, Harvard, Vancouver, ISO, and other styles

16

Narayan, Smriti, Sonu Kumar Gupta, Priyanka Singh, Villayat Ali, and Malkhey Verma. "Non-alcoholic fatty liver disease progression and current research." Asian Pacific Journal of Health Sciences 6, no. 1 (2019): 189–98. http://dx.doi.org/10.21276/apjhs.2019.6.1.26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Singla, Bharti, Gesu Singla, and Harsharan Kaur. "Lipid profile variations in non alcoholic fatty liver disease." Asian Pacific Journal of Health Sciences 6, no. 3 (2019): 1–4. http://dx.doi.org/10.21276/apjhs.2019.6.3.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Kumar, Kuldeep. "Iron Homeostasis in Patients with Nonalcoholic Fatty Liver Disease." Journal of Advanced Research in Medicine 08, no. 02 (2021): 6–10. http://dx.doi.org/10.24321/2349.7181.202107.

Full text

Abstract:

Introduction: Serum ferritin correlates with hepatic iron deposition in patients with Non Alcoholic Fatty Liver Disease (NAFLD). Iron removal improves insulin sensitivity thereby delaying the onset of type 2 diabetes mellitus, improves liver function and NAFLD histology. Objectives: This study was done to assess the iron status in NAFLD patients and its association with fibrosis and metabolic syndrome in NAFLD. Material and Method: The study was conducted in the Department of Medicine, GTB Hospital, Delhi from November 2017 - October 2019. It was an Analytical, comparative study. Forty patient

APA, Harvard, Vancouver, ISO, and other styles

19

Fitzpatrick, Emer. "PAEDIATRIC NON ALCOHOLIC FATTY LIVER DISEASE: AN EMERGING THREAT." Paediatrics Today 11, no. 1 (2015): 1–9. http://dx.doi.org/10.5457/p2005-114.104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

DELLA CORTE, Claudia. "PEDIATRIC NON-ALCOHOLIC FATTY LIVER DISEASE: A GROWING PROBLEM." Paediatrics Today 11, no. 2 (2015): 81–83. http://dx.doi.org/10.5457/p2005-114.114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Hidig, Sakarie Mustafe. "Navigating the Complexity of Non-Alcoholic Fatty Liver Disease." International Journal of Surgery & Surgical Techniques 8, no. 2 (2024): 1–2. http://dx.doi.org/10.23880/ijsst-16000220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Valenzuela-Vallejo, Laura, Despina Sanoudou, and Christos S. Mantzoros. "Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease." Journal of Personalized Medicine 13, no. 5 (2023): 830. http://dx.doi.org/10.3390/jpm13050830.

Full text

Abstract:

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, and is related to fatal and non-fatal liver, metabolic, and cardiovascular complications. Its non-invasive diagnosis and effective treatment remain an unmet clinical need. NAFLD is a heterogeneous disease that is most commonly present in the context of metabolic syndrome and obesity, but not uncommonly, may also be present without metabolic abnormalities and in subjects with normal body mass index. Therefore, a more specific pathophysiology-based subcategorization of fatty liver disease (FLD) is needed to be

APA, Harvard, Vancouver, ISO, and other styles

23

Perdomo, Carolina M., Nuria Garcia-Fernandez, and Javier Escalada. "Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?" Journal of Clinical Medicine 10, no. 9 (2021): 2040. http://dx.doi.org/10.3390/jcm10092040.

Full text

Abstract:

Non-alcoholic fatty liver disease is a highly prevalent disease worldwide with a renowned relation to cardiovascular disease and chronic kidney disease. These diseases share a common pathophysiology including insulin resistance, oxidative stress, chronic inflammation, dysbiosis and genetic susceptibilities. Non-alcoholic fatty liver disease is especially prevalent and more severe in type 2 diabetes. Patients with non-alcoholic fatty liver disease should have liver fibrosis assessment in order to identify those at the highest risk of adverse outcomes so that appropriate management strategies ca

APA, Harvard, Vancouver, ISO, and other styles

24

Mahmood, Kawa Abdullah. "PREVALENCE OF FATTY PANCREAS AMONG PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN SULAIMANI." Journal of Sulaimani Medical College 6, no. 2 (2016): 107–15. http://dx.doi.org/10.17656/jsmc.10094.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Fusillo, Steven, and Bryan Rudolph. "Nonalcoholic Fatty Liver Disease." Pediatrics in Review 36, no. 5 (2015): 198–206. http://dx.doi.org/10.1542/pir.36-5-198.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Ko, Jae Sung. "Nonalcoholic Fatty Liver Disease." Korean Journal of Gastroenterology 56, no. 1 (2010): 6. http://dx.doi.org/10.4166/kjg.2010.56.1.6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Wang, Xiao Jing, and Harmeet Malhi. "Nonalcoholic Fatty Liver Disease." Annals of Internal Medicine 169, no. 9 (2018): ITC65. http://dx.doi.org/10.7326/aitc201811060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Makri, Evangelia S., and Stergios A. Polyzos. "Nonalcoholic fatty liver disease." Journal of Atherosclerosis Prevention and Treatment 13, no. 1 (2022): 17–25. http://dx.doi.org/10.53590/japt.02.1030.

Full text

Abstract:

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease affecting millions of people worldwide with potentially serious complications that may lead to mortality and constitute a significant socioeconomic burden. Although modern lifestyle, obesity and insulin resistance play leading roles in the pathophysiology of the disease, various metabolic aberrations, as well as genetic predisposition participate in the development and progression of NAFLD. The diagnosis of NAFLD, especially the early recognition of NASH and fibrosis, is vital for the early management of the disease. Many diag

APA, Harvard, Vancouver, ISO, and other styles

29

Bessette, Michael. "Nonalcoholic Fatty Liver Disease." Physician Assistant Clinics 6, no. 4 (2021): 667–75. http://dx.doi.org/10.1016/j.cpha.2021.05.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Thrasher, T., and M. F. Abdelmalek. "Nonalcoholic Fatty Liver Disease." North Carolina Medical Journal 77, no. 3 (2016): 216–19. http://dx.doi.org/10.18043/ncm.77.3.216.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Angulo, Paul. "Nonalcoholic Fatty Liver Disease." New England Journal of Medicine 346, no. 16 (2002): 1221–31. http://dx.doi.org/10.1056/nejmra011775.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Polyzos, Stergios A., Jannis Kountouras, Christos Zavos, and Georgia Deretzi. "Nonalcoholic Fatty Liver Disease." Journal of Clinical Gastroenterology 46, no. 4 (2012): 272–84. http://dx.doi.org/10.1097/mcg.0b013e31824587e0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Filipović, Branka, Alastair Forbes, Bojan Tepeš, and Dan L. Dumitraşcu. "Nonalcoholic Fatty Liver Disease." Canadian Journal of Gastroenterology and Hepatology 2018 (July 31, 2018): 1–2. http://dx.doi.org/10.1155/2018/2097435.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Fitzgerald, Margaret A. "Nonalcoholic Fatty Liver Disease." Nurse Practitioner 32, no. 2 (2007): 6???7. http://dx.doi.org/10.1097/00006205-200702000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Feagins, Linda A., Avegail Flores, Cristina Arriens, et al. "Nonalcoholic fatty liver disease." European Journal of Gastroenterology & Hepatology 27, no. 10 (2015): 1154–60. http://dx.doi.org/10.1097/meg.0000000000000421.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Clark, Jeanne M., Frederick L. Brancati, and Anna Mae Diehl. "Nonalcoholic fatty liver disease." Gastroenterology 122, no. 6 (2002): 1649–57. http://dx.doi.org/10.1053/gast.2002.33573.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Sivell, Christopher. "Nonalcoholic Fatty Liver Disease." Gastroenterology Nursing 42, no. 5 (2019): 428–34. http://dx.doi.org/10.1097/sga.0000000000000443.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

You, Jie, Sha Huang, Gui-Qian Huang, et al. "Nonalcoholic Fatty Liver Disease." Medicine 94, no. 5 (2015): e479. http://dx.doi.org/10.1097/md.0000000000000479.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Adams, L. A. "Nonalcoholic fatty liver disease." Canadian Medical Association Journal 172, no. 7 (2005): 899–905. http://dx.doi.org/10.1503/cmaj.045232.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Hardy, Timothy, Quentin M. Anstee, and Christopher P. Day. "Nonalcoholic fatty liver disease." Current Opinion in Gastroenterology 31, no. 3 (2015): 175–83. http://dx.doi.org/10.1097/mog.0000000000000175.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Alfie, Marcos E., and William R. Treem. "Nonalcoholic Fatty Liver Disease." Pediatric Annals 35, no. 4 (2006): 290–99. http://dx.doi.org/10.3928/0090-4481-20060401-14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Lall, Chandana G., Alex M. Aisen, Navin Bansal, and Kumaresan Sandrasegaran. "Nonalcoholic Fatty Liver Disease." American Journal of Roentgenology 190, no. 4 (2008): 993–1002. http://dx.doi.org/10.2214/ajr.07.2052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Pierantonelli, Irene, and Gianluca Svegliati-Baroni. "Nonalcoholic Fatty Liver Disease." Transplantation 103, no. 1 (2019): e1-e13. http://dx.doi.org/10.1097/tp.0000000000002480.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Zhao, Yan-Ci, Guo-Jun Zhao, Ze Chen, Zhi-Gang She, Jingjing Cai, and Hongliang Li. "Nonalcoholic Fatty Liver Disease." Hypertension 75, no. 2 (2020): 275–84. http://dx.doi.org/10.1161/hypertensionaha.119.13419.

Full text

Abstract:

Hypertension, a multifactorial disorder resulting from the interplay between genetic predisposition and environmental risk factors, affects ≈30% of adults. Emerging evidence has shown that nonalcoholic fatty liver disease (NAFLD), as an underestimated metabolic abnormality, is strongly associated with an increased risk of incident prehypertension and hypertension. However, the role of NAFLD in the development of hypertension is still obscure and is highly overlooked by the general public. Herein, we highlight the epidemiological evidence and putative mechanisms focusing on the emerging roles o

APA, Harvard, Vancouver, ISO, and other styles

45

Day, Christopher, and Quentin Anstee. "Nonalcoholic Fatty Liver Disease." Seminars in Liver Disease 35, no. 03 (2015): 203–6. http://dx.doi.org/10.1055/s-0035-1562941.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Li, Ding-You, Min Yang, Sarah Edwards, and Shui-Qing Ye. "Nonalcoholic Fatty Liver Disease." Journal of Parenteral and Enteral Nutrition 37, no. 6 (2013): 787–93. http://dx.doi.org/10.1177/0148607113481623.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Grant, Lafaine M., and Mauricio Lisker-Melman. "Nonalcoholic fatty liver disease." Annals of Hepatology 3, no. 3 (2004): 93–99. http://dx.doi.org/10.1016/s1665-2681(19)32100-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Levy, A. D. "Nonalcoholic Fatty Liver Disease." Yearbook of Diagnostic Radiology 2009 (January 2009): 264. http://dx.doi.org/10.1016/s0098-1672(09)79307-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Sweet, Patrick H., Teresa Khoo, and Steven Nguyen. "Nonalcoholic Fatty Liver Disease." Primary Care: Clinics in Office Practice 44, no. 4 (2017): 599–607. http://dx.doi.org/10.1016/j.pop.2017.07.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Valva, Pamela, Daniela Rios, Paola Casciato, et al. "Nonalcoholic fatty liver disease." European Journal of Gastroenterology & Hepatology 30, no. 6 (2018): 637–44. http://dx.doi.org/10.1097/meg.0000000000001079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!